BR112023025242A2 - Vetor de liberação de sirna - Google Patents
Vetor de liberação de sirnaInfo
- Publication number
- BR112023025242A2 BR112023025242A2 BR112023025242A BR112023025242A BR112023025242A2 BR 112023025242 A2 BR112023025242 A2 BR 112023025242A2 BR 112023025242 A BR112023025242 A BR 112023025242A BR 112023025242 A BR112023025242 A BR 112023025242A BR 112023025242 A2 BR112023025242 A2 BR 112023025242A2
- Authority
- BR
- Brazil
- Prior art keywords
- agent
- negatively charged
- phosphonium
- therapeutic
- sirna
- Prior art date
Links
- 108020004459 Small interfering RNA Proteins 0.000 title abstract 3
- 239000013598 vector Substances 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 5
- QNHQEUFMIKRNTB-UHFFFAOYSA-N aesculetin Natural products C1CC(=O)OC2=C1C=C(O)C(O)=C2 QNHQEUFMIKRNTB-UHFFFAOYSA-N 0.000 abstract 3
- 239000000032 diagnostic agent Substances 0.000 abstract 3
- 229940039227 diagnostic agent Drugs 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- ILEDWLMCKZNDJK-UHFFFAOYSA-N esculetin Chemical compound C1=CC(=O)OC2=C1C=C(O)C(O)=C2 ILEDWLMCKZNDJK-UHFFFAOYSA-N 0.000 abstract 3
- 229940124597 therapeutic agent Drugs 0.000 abstract 3
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000000170 cell membrane Anatomy 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000013603 viral vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
- C07F9/65522—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Oscillators With Electromechanical Resonators (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202111024926 | 2021-06-04 | ||
| PCT/IB2022/055214 WO2022254405A1 (en) | 2021-06-04 | 2022-06-03 | siRNA DELIVERY VECTOR |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023025242A2 true BR112023025242A2 (pt) | 2024-02-20 |
Family
ID=82558096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023025242A BR112023025242A2 (pt) | 2021-06-04 | 2022-06-03 | Vetor de liberação de sirna |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240277851A1 (https=) |
| EP (1) | EP4346902A1 (https=) |
| JP (1) | JP2024521209A (https=) |
| CN (1) | CN117396227A (https=) |
| AU (1) | AU2022287326A1 (https=) |
| BR (1) | BR112023025242A2 (https=) |
| CA (1) | CA3220535A1 (https=) |
| WO (1) | WO2022254405A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116159145B (zh) * | 2023-01-31 | 2025-04-22 | 四川大学 | 含七叶皂苷和/或其盐化合物的转染复合物在促转染的应用 |
| CN120617243A (zh) * | 2024-11-15 | 2025-09-12 | 江苏省肿瘤医院 | 瑞香素作为抑制剂在制备治疗三阴性乳腺癌的药物中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2540234B (en) * | 2015-02-19 | 2020-12-02 | Council Scient Ind Res | An antioxidant compound having anti atherosclerotic effect and preparation thereof |
| US11213960B2 (en) | 2018-09-17 | 2022-01-04 | John AMBIELLI | Multi-tool and storage device |
| AR127082A1 (es) * | 2019-11-22 | 2023-12-20 | Council Scient Ind Res | Compuestos antiinflamatorios para el tratamiento de trastornos cutáneos |
-
2022
- 2022-06-03 AU AU2022287326A patent/AU2022287326A1/en active Pending
- 2022-06-03 JP JP2023574125A patent/JP2024521209A/ja active Pending
- 2022-06-03 CA CA3220535A patent/CA3220535A1/en active Pending
- 2022-06-03 WO PCT/IB2022/055214 patent/WO2022254405A1/en not_active Ceased
- 2022-06-03 EP EP22741839.9A patent/EP4346902A1/en active Pending
- 2022-06-03 US US18/562,733 patent/US20240277851A1/en active Pending
- 2022-06-03 BR BR112023025242A patent/BR112023025242A2/pt unknown
- 2022-06-03 CN CN202280036975.2A patent/CN117396227A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3220535A1 (en) | 2022-12-08 |
| US20240277851A1 (en) | 2024-08-22 |
| WO2022254405A1 (en) | 2022-12-08 |
| AU2022287326A1 (en) | 2023-11-30 |
| JP2024521209A (ja) | 2024-05-28 |
| EP4346902A1 (en) | 2024-04-10 |
| CN117396227A (zh) | 2024-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pu et al. | Sono‐controllable and ROS‐sensitive CRISPR‐Cas9 genome editing for augmented/synergistic ultrasound tumor nanotherapy | |
| ES3025685T3 (en) | Genetically modified bacteria and methods for genetic modification of bacteria | |
| BR112023025242A2 (pt) | Vetor de liberação de sirna | |
| BR112013026494A2 (pt) | composto, composição farmacêutica, método para tratar condição | |
| BR112015000174A2 (pt) | método para o tratamento da artrite | |
| BR112017013597A2 (pt) | molécula de ácido nucleico, composição farmacêutica, vetor ou célula, e, método para tratamento de uma doença. | |
| BR0307661A (pt) | Terapia para câncer | |
| BR112012015499A2 (pt) | método de tratamento de fibrilação atrial | |
| BR112023018944A2 (pt) | Composição de terapia gênica e tratamento de cardiomiopatia arritmogênica ventricular direita | |
| BR112018068906A2 (pt) | composição, método, método de redução de risco, prevenção ou tratamento de um indivíduo que tem uma doença ou distúrbio autoimune, método de indução de degradação de uma proteína-alvo numa célula, método para reduzir o risco, prevenir ou tratar um estado da doença ou afecção num paciente em que a atividade proteica desregulada é responsável pelo referido estado da doença ou afecção, método para reduzir o risco, prevenir ou tratar câncer num indivíduo e método de tratamento de uma doença ou distúrbio genético num indivíduo | |
| BR112022013270A2 (pt) | Sistemas e composições farmacêuticas para tratamento por injeção direta de uma população alvo de células | |
| BR112017005078A2 (pt) | sistema para liberação direcionada de agentes terapêuticos ao tecido | |
| BR112018008344A2 (pt) | molécula de ácido nucleico, composição farmacêutica, vetor ou célula, método para prevenir, tratar ou melhorar uma doença, e, uso de uma composição | |
| BR112023002453A2 (pt) | Composições de agente de via de estresse de replicação e métodos para tratar câncer | |
| ZA202206418B (en) | Amphiregulin gene-specific double-stranded oligonucleotide and composition for preventing and treating fibrosis-related diseases and respiratory diseases, comprising same | |
| BRPI0810384B8 (pt) | terapia enzimática anticâncer | |
| Bhat et al. | The potential of CRISPR-guided therapies in the dermatology clinic | |
| Liu et al. | Effects of Dimethylaminoethanol and Compound Amino Acid on D‐Galactose Induced Skin Aging Model of Rat | |
| McColloch et al. | Alterted adipogenesis of human mesenchymal stem cells by photobiomodulation using 1064 nm laser light | |
| WO2019010301A8 (en) | Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap) | |
| Kumar et al. | Understanding the activating mechanism of the immune system against COVID-19 by Traditional Indian Medicine: Network pharmacology approach | |
| BR112013002945A2 (pt) | composição farmacâutica formulada com agente de eco-contraste de microbolhas e um ácido nucleico terapêutico de interesse para uso em um método para tratamento de uma doença ocular em um sujeito | |
| Yu et al. | Biologically produced and metal-organic framework delivered dual-cut CRISPR/Cas9 system for efficient gene editing and sensitized cancer therapy | |
| CN106222173B (zh) | circRNA MNCR在调节心肌细胞坏死和心肌缺血损伤中的作用 | |
| Yin et al. | Gastrodin from Gastrodia elata attenuates acute myocardial infarction by suppressing autophagy: key role of the miR-30a-5p/ATG5 pathway |